Pivekimab, referred to as IBAT®, is a unique synthesized monoclonal antibody developed for specifically interact with and neutralize IL-6 cytokine, the key cytokine associated in multiple disease mechanisms driving https://socialrus.com/story24805036/pivekimab-the-deep-examination-of-a-synthetic-monoclonal-antibody